HCG Manavata Cancer Centre performs first PIPAC procedure for advanced abdominal cancer

Mumbai: HCG Manavata Cancer Centre (HCGMCC) has successfully performed its first PIPAC (Pressurised IntraPeritoneal Aerosol Chemotherapy) procedure—an advanced, minimally invasive surgical technique used in the management of advanced abdominal cancers. The pioneering procedure was performed on a patient diagnosed with advanced-stage stomach cancer.

The surgery was conducted under the expert guidance of Dr. Ninad Katdare from HCG Cancer Centre, Mumbai, in collaboration with Dr. Raj Nagarkar, Managing Director and Chief of Surgical Oncology and Robotic Services at HCGMCC.

PIPAC is widely adopted in international oncology centers for treating peritoneal cancers deemed inoperable by conventional standards. This includes cancers originating in the stomach, ovaries, and colon.

“The breakthrough technique allows chemotherapy to be delivered directly into the peritoneal cavity in aerosolized form using laparoscopic access.

The pressurized delivery improves drug penetration, allowing for targeted treatment with minimal systemic side effects. It not only maximizes the therapeutic effect of chemotherapy but also enhances patient comfort and recovery,” said Prof. Dr. Raj Nagarkar, Chief of Surgical Oncology and Robotic Services and Managing Director, KIMS Manavata Hospitals, HCG Manavata Cancer Centre and Six Sigma, Nashik.

The key advantages of PIPAC include localised, high-concentration drug delivery directly into the peritoneal cavity, which enhances the therapeutic impact on cancerous tissues.

It minimises toxicity to healthy organs, thereby reducing systemic side effects commonly associated with traditional chemotherapy. Patients also benefit from faster postoperative recovery due to the minimally invasive nature of the procedure.